Chapter
3. Immune System in the Therapeutic Response in BC. The Immunogenic Cell Death
4. T-Infiltrating Lymphocytes Molecular and Genomic Characterization as a Strategic Tool to Better Understand BC Behavior
5. Neoantigen Prediction: Genomic Tools for Personalized Immunotherapy
6. Immunotherapeutic Approaches in BC. Clinical Trials With Immune Checkpoint Inhibitors
6.1. Early Results in Clinical Trials With Immune Checkpoints as Single Therapy
6.1.1. A Phase Ib Multicohort Study of MK-3475 in Subjects With Advanced Solid Tumors (Keynote-012). NCI01848834
6.1.2. Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors (Keynote-028). NCT02054806
6.1.3. A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Atezolizumab Administered Intra ...
6.2. Early Results in Clinical Trials With Immune Checkpoints in the Context of Combinations
6.2.1. A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Bevacizumab and/or With Chemothe ...
6.3. Ongoing and Planned Clinical Trials With Immune Checkpoints Inhibitors in BC
Chapter Two: New Insights Into Cellular Stress Responses to Environmental Metal Toxicants
2.1. Activation of UPR Signaling
2.2. ER Stress-Induced Apoptosis
3. Metal-Induced ER Stress
3.1. Mechanisms of Metal-Induced ER Stress
3.2. Metal-Induced ER Stress and Human Disease
3.2.1. Arsenic-Induced ER Stress in Metabolic Diseases
3.2.2. Cadmium Nephrotoxicity and ER Stress
3.2.3. Lead Neurotoxicity and ER Stress
3.2.4. Manganese (Mn) and Neurotoxicity
4. ER Stress and Its Impact on Oxidative Stress
4.1. ROS Formation in Mitochondria
4.2. ROS Formation by Oxidative Protein Folding in ER
4.3. Interplay Between Oxidative Stress and ER Stress
5. Genomics Approaches in Metal-Induced Cell Stress Studies
5.2. Functional Genomic Screening
5.2.2. CRISPR/Cas9 Functional Screening
6. Conclusions and Future Directions
Chapter Three: An Update on Src Family of Nonreceptor Tyrosine Kinases Biology
2. Regulation of SFKs Function
3. Redox-Dependent Regulation of SFK Function
4. Role of SFKs in PRL Signaling
5. Relevance of SFKs in Breast Cancer
5.1. SFKs and Breast Cancer Stem Cells
6. Role of SFKs During Mammalian Embryo Development and in the Regulation of Embryonic and Somatic Stem Cells
Chapter Four: STAT Transcription Factors in T Cell Control of Health and Disease
1. Engagement of the Jak-STAT Signaling Pathway
2. Jak-STAT Molecules in T Helper Cell Differentiation
3. STAT Molecules in the Development of Cytotoxic T Cells
4. STATs Mutations Result in Patient Immunodeficiency
5. STAT Molecules in Allergic Inflammation
5.1. Jak Proteins in Allergic Inflammation
6. Role of STAT Molecules in Intestinal Inflammation
7. Jak-STAT Molecules in Autoimmune Diseases
8. Blocking Cytokine Signaling to Treat Disease
Chapter Five: Chemokine Receptor Signaling and the Hallmarks of Cancer
2. The Chemokine Superfamily
2.1. Chemokines, the Ligands
2.2. Signal Transduction by Chemokine Receptors
3. Chemokine Activity on Neoplastic Cells
3.1. Chemokine Signaling Sustains Tumor Cell Proliferation
3.2. Chemokines Interact With Tumor Suppressor Genes
3.3. Chemokines as Regulators of Apoptosis in Cancer Cells
3.4. Chemokines as Drivers and Cues for Tumor Invasion and Metastasis
3.5. Chemokines and Cancer Stem Cell Plasticity
4. Chemokine Activities on Stromal Cells
4.1. Chemokines as Positive and Negative Regulators of Tumor Vascularization
4.2. Chemokines as Shapers of the Tumor Inflammatory Milieu
Chapter Six: Mitochondrion: A Common Organelle for Distinct Cell Deaths?
4.1. Introduction and Molecular Mechanisms
4.2. Mitophagy and Cell Death
4.3. Mitophagy, Cytoprotection, and Mitochondrial Quality Control
5. Implication of Mitophagy in Models of Neurological Diseases
6. Implication of Mitochondria-Dependent Cell Death in Cardiac Diseases
6.1. Outer Membrane Proteins
6.2. Intermembrane Space Proteins
6.3. Inner Membrane Proteins
7. Conclusion and Perspectives
Chapter Seven: Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches
3. Effector Mechanisms and Activity of Tumor-Targeting Antibodies
3.1. Antibody-Dependent Cellular Cytotoxicity
3.2. Antibody-Dependent Cellular Phagocytosis
3.3. Complement-Dependent Cytotoxicity
3.4. Signaling Modulation
4. Immunomodulatory Antibodies
4.1. Checkpoint Blocking mAbs
4.2. Immunostimulatory mAbs That Target the TNFR Superfamily
5. Antibody Engineering to Improve Effector Functions
5.2. Amino Acid Sequence Modifications
5.3. N-Glycan Structure Modification
6. Alternative Antibody Formats
6.1. Antigen-Binding Fragments
6.2. Bispecific Antibodies
6.2.1. Immune-Retargeting bsAbs
6.2.2. Direct Tumor Targeting With bsAbs
7. Antibody-Drug Conjugates
7.1.1. Improvement Strategies for ADCs
8. Antibody-Cytokine Fusion Proteins
8.3. TNF Superfamily Ligands
8.3.1. TNF-related apoptosis-inducing ligand
9. CAR-Transfected T Cells
International Review of Cell and Molecular Biology
( Volume 331 )
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
